Compare Eli Lilly And Co (LLY) vs Zillow Group Inc Class A (ZG) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Zillow Group (ZG) trades at $29.87, up 6.79% on the day, showing strong momentum despite mixed technical signals. The company has demonstrated improved financial performance with revenue growth from $2.2B in 2024 to $2.6B in 2025 and achieving profitability with $23M net income after three years of losses. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though Q4 2025 missed expectations. Analyst consensus remains divided with a Hold rating but offers significant upside potential with a $48.87 price target.

The outlook for ZG appears cautiously optimistic with fundamental improvement offset by housing market headwinds. Investment opportunity lies in the company's transition to profitability and market share gains in digital real estate, while risks include interest rate sensitivity, competitive pressures from Compass, and ongoing housing affordability challenges that could impact transaction volumes.